Forbion leads Promedior's $12 million series C round
This article was originally published in Scrip
Promedior has raised $12 million in a series C financing round. The clinical-stage US biotechnology company is developing therapies to treat inflammatory and fibrotic diseases. Forbion Capital Partners, the only new investor, led the round with participation from existing investors Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, and Easton Capital.